Big pharmaceuticals groups are ill-prepared for the squeeze on smaller biotech companies and may see pivotal research partnerships jeopardised by the credit crunch, a report has warned.

The growing weakness of smaller biotech companies risks ensnaring even the strongest pharma groups, harming a central part of the relationships necessary for innovative medicines.